Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

JAENS PHARMACEUTICAL INDUSTRIES PVT LTD

Private pharmaceutical manufacturer · Sheikhupura · Pakistan

Sheikhupura-based pharmaceutical manufacturer established in 2004 with registered products across oral, injectable, ophthalmic and topical dosage forms.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation25 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date30 Jul 2026Newest effective date among published current price records
Corporate profile evidence3 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Jaens Pharmaceutical Industries (Pvt.) Ltd.
Company type
Private pharmaceutical manufacturer
Address
28 KM Lahore-Sheikhupura Road, Sheikhupura, Pakistan
Corporate source details checked
16 Aug 2026
Corporate profile completeness
75%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000532 Jaens Pharmaceutical Industries (Pvt) Ltd. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000532 60 linked products · source seen 25 Sep 2026 View source ↗
Corporate profile source ledger Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx62public portfolio records represented
REG55unique registrations represented
IDX5indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER2registry-verified exact registrations
PKR60current validated price records
G34generic molecules in indexed catalogue
DF7dosage-form groups
TA11therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage97%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage87%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixJAENS PHARMACEUTICAL INDUSTRIES PVT LTDShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/jaens-pharmaceutical-industries-pvt-ltdGenerated 25 Sep 2026Anti-infectives33 · 55%Cardiovascular6 · 10%Gastrointestinal & hepatology5 · 8%Ophthalmology3 · 5%Anesthesia & critical care3 · 5%Fluids & supportive care3 · 5%Dermatology2 · 3%Other therapeutic areas5 · 8%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioJAENS PHARMACEUTICAL INDUSTRIES PVT LTDDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/jaens-pharmaceutical-industries-pvt-ltdGenerated 25 Sep 202660presentationsTablet28 · 47%Injection11 · 18%Capsule8 · 13%Drops7 · 12%Ointment3 · 5%Cream2 · 3%Other forms1 · 2%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionJAENS PHARMACEUTICAL INDUSTRIES PVT LTDCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/jaens-pharmaceutical-industries-pvt-ltdGenerated 25 Sep 202652comparable productsBelow peer median28 · 54%Near peer median14 · 27%Above peer median10 · 19%Company median price position-7.9%Lowest-price equivalents4Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsJAENS PHARMACEUTICAL INDUSTRIES PVT LTDCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/jaens-pharmaceutical-industries-pvt-ltdGenerated 25 Sep 2026Mediate Pharmaceutical Pvt Ltd23 shared68% overlapEpharm Laboratories23 shared68% overlapNabiqasim Industries (Pvt) Ltd.,22 shared65% overlapPharmasol (Pvt) Ltd.22 shared65% overlapNeutro Pharma (Pvt.) Ltd.,22 shared65% overlapM/s. Genix Pharma (Pvt) Ltd.21 shared62% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives33 products · 55%
Cardiovascular6 products · 10%
Gastrointestinal & hepatology5 products · 8%
Ophthalmology3 products · 5%
Anesthesia & critical care3 products · 5%
Fluids & supportive care3 products · 5%
Dermatology2 products · 3%
Respiratory & allergy2 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Fluoroquinolone antibacterials8 products · 13%
Macrolide antibacterials5 products · 8%
Third-generation cephalosporins4 products · 7%
Proton pump inhibitors4 products · 7%
Glaucoma medicines3 products · 5%
Nitroimidazole anti-infectives3 products · 5%
Local anesthetics3 products · 5%
Antimalarials3 products · 5%
Formulation footprint

Dosage forms

Tablet28 products
Injection11 products
Capsule8 products
Drops7 products
Ointment3 products
Cream2 products
Suspension1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 AZALAzithromycin 3presentations 250 mg, 500 mg · Tablet, Capsule #2 DazoMetronidazole 3presentations 200 mg, 400 mg · Tablet #3 DicipCiprofloxacin 3presentations 250 mg, 3 mg/mL (0.3%), 500 mg · Tablet, Drops #4 DongcainLidocaine 3presentations 1 %, 1% · Injection #5 JasortinAtorvastatin 3presentations 10 mg, 20 mg, 40 mg · Tablet #6 THAITANLosartan 3presentations 100 mg, 25 mg, 50 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2854% of comparable products
Near market median14within ±5% of median
Above market median1019% of comparable products
Lowest-price equivalents4ties included
Company median price position -7.9% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Dongcain 1%Lidocaine · Injection · 3.5ml PKR 1.17/mL-55.5% vs market median Dongcain 1 %Lidocaine · Injection · 2ml PKR 2.05/mL-43.1% vs market median Water for 10 mLWater for Injection · Injection · 1x10ml PKR 1.21/mL-42.3% vs market median Dazo 200 mgMetronidazole · Tablet · 20x10's PKR 1.33/tablet-38.0% vs market median Dazo 400 mgMetronidazole · Tablet · 2x10's PKR 1.90/tablet-37.0% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 23shared generics Epharm Laboratories144 products · 67 generics 23shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 22shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 22shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 22shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 21shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers53Distinct registrations among indexed, published, presentation-validated products only
Verified price observations60
Products with a verified price60
Products with multiple price observations0
Source records with multiple versions60
Latest portfolio source check22 Sep 2026
Latest effective price date30 Jul 2026
Latest source observation25 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

55 unique registration(s) · 5 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaAnti-infectives Drug classMacrolide antibacterials Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
AZAL Azithromycin 250 mg Tablet 1x10's 032650 PKR 427.65 PKR 42.77/tablet 9% below median
AZAL Azithromycin 500 mg Tablet 6's 106189 PKR 412.68 PKR 68.78/tablet 19% below median
AZAL Azithromycin 250 mg Capsule 6's 108167 PKR 229.61 PKR 38.27/capsule 23% below median
CALARIDE Clarithromycin 250 mg Tablet 1x10's 032654 PKR 488.74 PKR 48.87/tablet Near median
CALARIDE Clarithromycin 500 mg Tablet 1x10's 032655 PKR 887.56 PKR 88.76/tablet 6% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). JAENS PHARMACEUTICAL INDUSTRIES PVT LTD — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 25, 2026, from https://medinfobase.com/company/jaens-pharmaceutical-industries-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.